Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4

NCT00277862 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT00277862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4
Lead sponsor
Ain Shams University
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2002
Completion date
April 30, 2007
Enrollment
280 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c